The enzyme elevation pattern was usually cholestatic with minimal elevations of AST and ALT.Decreased WBC (less than 1 x 10[9]/L), platelet count (less than 50 x 10[9]/L), and hemoglobin (less than 8 g/dL) were reported in up to 4%, up to 4%, and 3% of patients, respectively.Many reports of extended-release tablets in the stool occurred in patients with anatomic (including ileostomy or Psychotic disorder, confusional state, depersonalization, depression, disorientation, manic behavior, hallucination, abnormal behavior, and/or abnormal dreams usually resolved after the drug was stopped.Increased alkaline phosphatase (greater than 5 x ULN) was reported in up to 2% of patients.The incidence of dyspnea was similar for patients treated with 1 to 2 g/day, but was generally about 3 to 4 times as frequent for those treated with 4 g/day.Uveitis was reported primarily in patients treated with concomitant rifabutin; most cases were reversible.A case of corneal opacities was reported in a patient with AIDS and Mycobacterium avium complex Elevated BUN (greater than 50 mg/dL) was reported in less than 1% of patients.In some cases of rhabdomyolysis, this drug was coadministered with 1.

Br J Gen Pract 46 (1996): 357-6017. You may report them to the The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records.

Geodon (ziprasidone) is an oral and injectable anti-psychotic drug used to treat psychoses such as schizophrenia and bipolar disorder. "Product Information. If experienced, these tend to have a Less Severe expression 1. The most common reactions associated with dropout in the ziprasidone-treated patients were:There were 2 dropouts for each of these reactions among ziprasidone patients (1%) compared to one placebo patient each for dystonia and rash (1%) and no placebo patients for the remaining adverse reactions.Adverse Reactions Occurring at an Incidence of 2% or More Among Ziprasidone-Treated Patients in Short-Term, Oral, Placebo-Controlled TrialsTable 12 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred during acute therapy (up to 3 weeks) in patients with bipolar mania, including only those reactions that occurred in 2% or more of patients treated with ziprasidone and for which the incidence in patients treated with ziprasidone was greater than the incidence in placebo-treated patients.Explorations for interactions on the basis of gender did not reveal any clinically meaningful differences in the adverse reaction occurrence on the basis of this demographic factor.Adverse Reactions Occurring at an Incidence of 1% or More Among Ziprasidone-Treated Patients in Short-Term Trials of Intramuscular ZiprasidoneTable 13 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred during acute therapy with intramuscular ziprasidone in 1% or more of patients.In these studies, the most commonly observed adverse reactions associated with the use of intramuscular ziprasidone (incidence of 5% or greater) and observed at a rate on intramuscular ziprasidone (in the higher dose groups) at least twice that of the lowest intramuscular ziprasidone group were The following adverse reactions have been identified during post-approval use of Geodon. Are you? It does this by blocking receptors on the nerves for several neurotransmitters, including The following may cause increases in levels of Geodon and more side effects:Some of the most common side effects associated with ziprasidone are:There is a slight risk (1 in 1500 patients) that ziprasidone by itself could significantly increase the QT interval. Eur J Clin Microbiol Infect D 18 (1999): 70-132.

Vangala R, Cernek PK "Hypersensitivity reaction to clarithromycin." It is unknown if Geodon is … Anderson G, Esmonde T, Coles S, et al "A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia." There is an even smaller risk (1 in 4000 patients) that it could cause a potentially serious change in the rhythm of the heart.The following findings are based on the short-term placebo-controlled premarketing trials for The following adverse reactions were the most commonly observed adverse reactions associated with the use of ziprasidone (incidence of 5% or greater) and not observed at an equivalent incidence among placebo-treated patients (ziprasidone incidence at least twice that for placebo): Schizophrenia trials (see Table 11)An analysis for dose response in the schizophrenia 4-study pool revealed an apparent relation of adverse reaction to dose for the following reactions:The incidence of reported EPS (which included the adverse reaction terms extrapyramidal syndrome, hypertonia, dystonia, dyskinesia, hypokinesia, tremor, paralysis and twitching) for ziprasidone-treated patients in the short-term, placebo-controlled schizophrenia trials was 14% vs. 8% for placebo. Ann Pharmacother 30 (1996): 30029. Am J Med 104 (1998): 395-631. Gavura SR, Nusinowitz S "Leukocytoclastic vasculitis associated with clarithromycin."

Symptoms of bipolar disorder in children and teens include having trouble concentrating, behaving in risky ways, and losing interest in activities they once enjoyed.

J Hosp Infect 19 (1991): 39-4619. Lee KL, Jim MH, Tang SC, Tai YT "QT prolongation and Torsades de pointes associated with clarithromycin." Wood M "The tolerance and toxicity of clarithromycin." Clarithromycin is a relatively new antibiotic of the macrolide family heralded for an improved side effect profile, dosing schedule, and microbiological activity relative to its parent compound, erythromycin. Clin Infect Dis 20 (1995): 1563-410. With treatment involving the use of antipsychotic medications and psychosocial treatment, schizophrenia patients can lead rewarding and meaningful lives.Bipolar disorder (or manic depression) is a mental illness characterized by depression, mania, and severe mood swings.

Fraschini F "Clinical efficacy and tolerance of two new macrolides, clarithromycin and josamycin, in the treatment of patients with acute exacerbations of chronic bronchitis." Chest 107 (1995): 1035-4014.